- The study addressed the need for precision medicine resources tailored to the Chinese population, which is often underrepresented in genomic data.
- Researchers conducted large-scale genome sequencing on 20,488 Hong Kong Genome Project participants across rare disease and population cohorts.
- The rare disease cohort achieved a 25% diagnostic rate, and 3.7% of the population cohort had pathogenic variants for dominant disorders.
- The authors concluded that existing European-centric gene panels overlook significant clinically important genetic variations in Chinese individuals.
- This project establishes a crucial reference for clinically relevant genetic variation, informing precision medicine implementation for underrepresented populations.
Advancing Precision Medicine Through Population-Specific Genomics
The integration of genomic data into clinical practice is steadily refining disease classification and personalizing treatment. In fields like oncology, genomic profiling already dictates post-surgical adjuvant therapy in endometrial carcinoma [1, 2] and defines prognostic subgroups in acute myeloid leukemia [3]. While genome and exome sequencing are valuable for diagnosing rare diseases, their utility is constrained by a critical gap: foundational genomic research has been conducted predominantly in populations of European descent [4, 5]. This creates significant uncertainty when applying findings and clinical guidelines to other ethnic groups [6, 7]. A recent large-scale study directly confronts this disparity by building a comprehensive genomic resource for the Chinese population, providing a model for more equitable precision medicine.
Establishing a Foundational Genomic Resource
To address the urgent need for more diverse genomic data, the Hong Kong Genome Project (HKGP) was launched to build a resource for precision medicine tailored specifically to the Chinese population. The project's initial report is based on large-scale genome sequencing and integrated analysis of over 20,000 participants, creating a substantial and clinically relevant dataset from a historically underrepresented demographic.
The study employed a dual-cohort design to maximize its clinical utility. The first group was a rare disease cohort of 2,227 patients with suspected genetic diseases, where sequencing aimed to provide a definitive diagnosis. The second was a larger population cohort of 18,261 participants who underwent genomic screening to identify medically actionable findings. This two-pronged strategy allows the HKGP to simultaneously improve diagnostic pathways for individuals with existing disease and establish a baseline for preventative and personalized medicine in the broader community.
Diagnostic Yield in Rare Diseases and Population Screening
The project's findings underscore the immediate clinical value of population-specific genomics. For the rare disease cohort, whole-genome sequencing achieved a diagnostic rate of 25%, identifying a definitive genetic cause for one in four patients, many of whom may have endured a lengthy diagnostic odyssey. This result confirms the utility of sequencing in complex cases. However, the study's most critical insights emerged from benchmarking these new data against existing genetic panels developed primarily from European ancestry data.
In the population cohort of 18,261 individuals, analysis revealed that 3.7% carried pathogenic or likely pathogenic variants for dominant disorders. The limitations of non-specific panels became even more apparent when assessing recessive conditions. While standard gene lists identified 48% of individuals as carriers for a recessive disorder, the HKGP's population-specific analysis discovered that 38 additional clinically important genes would have been completely missed in the Chinese population if relying solely on European-derived panels. This gap could lead to missed opportunities for carrier screening, genetic counseling, and informed reproductive planning, highlighting the necessity of population-specific reference data to ensure accurate risk assessment.
Pharmacogenomic Insights for Clinical Practice
Beyond disease diagnosis, the Hong Kong Genome Project generated pharmacogenomic data with direct implications for daily prescribing. The analysis revealed that nearly all participants harbored at least one actionable phenotype, which is a genetic variation known to influence an individual's response to specific medications. These variations can alter drug metabolism, efficacy, or the risk of adverse reactions, making them a key target for personalized medicine. The clinical scale of this finding is significant.
The authors calculated that this genetic information could inform nearly one million annual prescriptions in Hong Kong alone. For practicing physicians, this means that integrating population-specific pharmacogenomic data into patient care could help guide drug selection, optimize dosing, and mitigate adverse events on a massive scale. Such a system moves clinical practice away from a trial-and-error approach and toward a more precise, genetically informed model of medication management, ultimately improving both safety and efficacy.
A Blueprint for Global Genomic Equity
The Hong Kong Genome Project provides more than just immediate clinical findings; it establishes a vital infrastructure for the future of equitable healthcare. The project has created a curated Hong Kong Chinese reference for clinically relevant genetic variation, a tool essential for accurately interpreting genetic tests for individuals of Chinese ancestry. This resource helps correct for the historical over-reliance on European-centric genomic databases, which can lead to misinterpretation of variant significance.
Ultimately, the HKGP serves as a blueprint for implementing precision medicine in other underrepresented populations around the world. By demonstrating the feasibility and profound clinical value of building a population-specific genomic database, the project provides a scalable model for others to follow. This work emphasizes that achieving the full potential of genomic medicine requires a global effort to build diverse genetic resources, ensuring that improved diagnostics and personalized therapies are relevant and accessible to all patients, not just those of European descent.
References
1. Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature. 2013. doi:10.1038/nature12113
2. Concin N, Matías‐Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer. 2020. doi:10.1136/ijgc-2020-002230
3. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. New England Journal of Medicine. 2016. doi:10.1056/nejmoa1516192
4. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018. doi:10.1038/s41586-018-0579-z
5. Howard DM, Adams MJ, Clarke T, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nature Neuroscience. 2019. doi:10.1038/s41593-018-0326-7
6. Riccio M, Rosso A, Siena LM, et al. Measuring the health benefits of genome and exome sequencing: a systematic review of economic evaluations.. Frontiers in public health. 2025. doi:10.3389/fpubh.2025.1728978
7. Azuelos C, Marquis M, Laberge A. A systematic review of the assessment of the clinical utility of genomic sequencing: Implications of the lack of standard definitions and measures of clinical utility.. European journal of medical genetics. 2024. doi:10.1016/j.ejmg.2024.104925